Skip to main content

Impaired Glucose Tolerance

7
Pipeline Programs
11
Companies
11
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
375%
Peptide
125%
+ 9 programs with unclassified modality

On Market (1)

Approved therapies currently available

Pfizer
ALTACEApproved
ramipril
Pfizer
oral1991
2M Part D

Competitive Landscape

11 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
1
RosiglitazonePhase 4
RamiprilPhase 3Small Molecule
Pfizer
PfizerNEW YORK, NY
1 program
1
1
RamiprilPhase 3Small Molecule1 trial
Active Trials
NCT00044265Completed310Est. Nov 2004
Prevail Therapeutics
1 program
1
ExenatidePhase 4Peptide1 trial
Active Trials
NCT00546728Completed50Est. Jul 2011
Medica Corp
Medica CorpMA - Bedford
1 program
1
SubettaPhase 31 trial
Active Trials
NCT03725033Completed538Est. Mar 2020
Genfit
GenfitFrance - Loos
1 program
1
GFT505 80mgPhase 21 trial
Active Trials
NCT01275469Completed47Est. Jan 2010
Takeda
TakedaTOKYO, Japan
2 programs
VogliboseN/A1 trial
PioglitazonePHASE_31 trial
Active Trials
NCT01993927Completed742Est. Aug 2013
NCT00220961Completed602Est. Apr 2010
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.N/A1 trial
Active Trials
NCT00841867Completed24Est. Oct 2009
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
AspirinN/A1 trial
Active Trials
NCT00122447Completed84Est. May 2011
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Study to Investigate the Pathophysiology of Type 2 Diabetes in YouthN/A1 trial
Active Trials
NCT00536250Completed255Est. Mar 2017
Sound Pharmaceuticals
1 program
low glycemic indexN/A1 trial
Active Trials
NCT01386645Completed56Est. Aug 2019
GSK
GSKLONDON, United Kingdom
1 program
RamiprilPHASE_3Small Molecule1 trial
Active Trials
NCT00095654Completed5,000Est. Oct 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prevail TherapeuticsExenatide
PfizerRamipril
Medica CorpSubetta
TakedaPioglitazone
GSKRamipril
GenfitGFT505 80mg
Sound Pharmaceuticalslow glycemic index
TakedaVoglibose
Angeles TherapeuticsAll subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Daiichi SankyoAspirin
Human BioSciencesStudy to Investigate the Pathophysiology of Type 2 Diabetes in Youth

Clinical Trials (11)

Total enrollment: 7,708 patients across 11 trials

NCT00546728Prevail TherapeuticsExenatide

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

Start: Oct 2007Est. completion: Jul 201150 patients
Phase 4Completed
NCT00044265PfizerRamipril

Treatment of Pediatric Hypertension With Altace Trial

Start: Jul 2002Est. completion: Nov 2004310 patients
Phase 4Completed
NCT03725033Medica CorpSubetta

Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance

Start: Oct 2018Est. completion: Mar 2020538 patients
Phase 3Completed
NCT00220961TakedaPioglitazone

Actos Now for Prevention of Diabetes (ACT NOW)

Start: Jan 2004Est. completion: Apr 2010602 patients
Phase 3Completed
NCT00095654GSKRamipril

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

Start: Jul 2001Est. completion: Oct 20065,000 patients
Phase 3Completed
NCT01275469GenfitGFT505 80mg

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

Start: Jun 2009Est. completion: Jan 201047 patients
Phase 2Completed
NCT01386645Sound Pharmaceuticalslow glycemic index

Effect of Dietary Glycemic Index on Beta-cell Function

Start: Jul 2011Est. completion: Aug 201956 patients
N/ACompleted
NCT01993927TakedaVoglibose

Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

Start: Nov 2009Est. completion: Aug 2013742 patients
N/ACompleted
NCT00841867Angeles TherapeuticsAll subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.

The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism)

Start: Dec 2008Est. completion: Oct 200924 patients
N/ACompleted
NCT00122447Daiichi SankyoAspirin

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Start: May 2005Est. completion: May 201184 patients
N/ACompleted
NCT00536250Human BioSciencesStudy to Investigate the Pathophysiology of Type 2 Diabetes in Youth

Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

Start: Sep 2001Est. completion: Mar 2017255 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.